Vascular protectants for the treatment of atherosclerosis

Expert Rev Cardiovasc Ther. 2003 Sep;1(3):385-92. doi: 10.1586/14779072.1.3.385.

Abstract

AGI-1067, the monosuccinic acid ester of probucol, is a phenolic antioxidant member of a novel class of agents termed vascular protectants. It has strong antioxidant properties, equipotent to those of probucol, and anti-inflammatory properties. It inhibits gene expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 and has been effective at preventing atherosclerosis in all tested animal models. It also improved luminal dimensions of reference segments in the percutaneous coronary intervention (PCI) vessels in the CART-1 clinical trial, which suggests a direct anti-atherosclerosis effect. Two important trials that test the antioxidant/anti-inflammatory hypothesis are ongoing with AGI-1067: the Canadian Atherosclerosis and Restenosis Trial, which assesses its value for the reduction of both atherosclerosis progression in non-PCI vessels and post-PCI restenosis, and the Aggressive Reduction of Inflammation Stops Events trial, which is evaluating the effects of AGI-1067 on hard cardiovascular outcomes.

Publication types

  • Review

MeSH terms

  • Antioxidants / therapeutic use*
  • Coronary Artery Disease / prevention & control*
  • Humans
  • Probucol / analogs & derivatives*
  • Probucol / therapeutic use*
  • Protective Agents / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Research Design

Substances

  • Antioxidants
  • Protective Agents
  • succinobucol
  • Probucol